News Detail
London, 27 March 2025: GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years.
Blujepa, also known as gepotidacin, has been View Details
Source : Fierce Pharma
GSK
antibiotics
infectious disease
FDA approvals
drug approvals
antibiotic resistance
Related News
- Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer (30-03-2025)
- HC asks Centre, Delhi govt to disclose regulatory mechanism for blood banks in city (30-03-2025)
- Meghalaya’s Citrus offers hope against antibiotic resistance (30-03-2025)
- Counterfeit anti-rabies vaccine circulating in major Indian cities (30-03-2025)
- Delhi HC awards ₹30.91 lakh costs & damages to Himalaya (29-03-2025)
- Cardiac stents to cost 2% more as NPPA allows prices to be raised (29-03-2025)
- NPPA notifies revised prices based on WPI increase (29-03-2025)
- Seven Booked for Illegal Import and Sale of Medicines Without Bills (29-03-2025)
- IPC Flags Adverse Reactions to Metronidazole, Luliconazole, Dalteparin, Gliclazide, and Tramadol (29-03-2025)
- Himachal Pradesh Tightens Control on Drug Sales (29-03-2025)